Emergence of prions selectively resistant to combination drug therapy

Prions are unorthodox infectious agents that replicate by templating misfolded conformations of a host-encoded glycoprotein, collectively termed PrPSc. Prion diseases are invariably fatal and currently incurable, but oral drugs that can prolong incubation times in prion-infected mice have been developed. Here, we tested the efficacy of combination therapy with two such drugs, IND24 and Anle138b, in scrapie-infected mice. The results indicate that combination therapy was no more effective than either IND24 or Anle138b monotherapy in prolonging scrapie incubation times. Moreover, combination therapy induced the formation of a new prion strain that is specifically resistant to the combination regimen but susceptible to Anle138b. To our knowledge, this is the first report of a pathogen with specific resistance to combination therapy despite being susceptible to monotherapy. Our findings also suggest that combination therapy may be a less effective strategy for treating prions than conventional pathogens.

[1]  M. Morawski,et al.  Amyloid-Beta Peptides Trigger Aggregation of Alpha-Synuclein In Vitro , 2020, Molecules.

[2]  K. Doh-ura,et al.  Combining autophagy stimulators and cellulose ethers for therapy against prion disease , 2019, Prion.

[3]  S. Prusiner,et al.  Developing Therapeutics for PrP Prion Diseases. , 2017, Cold Spring Harbor perspectives in medicine.

[4]  J. Bartz.  Prion Strain Diversity. , 2016, Cold Spring Harbor perspectives in medicine.

[5]  B. Caughey,et al.  Factors That Improve RT-QuIC Detection of Prion Seeding Activity , 2016, Viruses.

[6]  S. Prusiner,et al.  Use of a 2-aminothiazole to Treat Chronic Wasting Disease in Transgenic Mice. , 2015, The Journal of infectious diseases.

[7]  Tuomas P. J. Knowles,et al.  On the lag phase in amyloid fibril formation , 2015, Physical chemistry chemical physics : PCCP.

[8]  K. Mehta,et al.  Burden of antibiotic resistance in common infectious diseases: role of antibiotic combination therapy. , 2014, Journal of clinical and diagnostic research : JCDR.

[9]  G. Telling,et al.  Quinacrine promotes replication and conformational mutation of chronic wasting disease prions , 2014, Proceedings of the National Academy of Sciences.

[10]  S. Prusiner,et al.  Drug resistance confounding prion therapeutics , 2013, Proceedings of the National Academy of Sciences.

[11]  G. Forloni,et al.  Therapy in prion diseases. , 2013, Current topics in medicinal chemistry.

[12]  P. Tavan,et al.  Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease , 2013, Acta Neuropathologica.

[13]  N. Makarava,et al.  Genesis of tramsmissible protein states via deformed templating , 2012, Prion.

[14]  Fei Wang,et al.  Isolation of phosphatidylethanolamine as a solitary cofactor for prion formation in the absence of nucleic acids , 2012, Proceedings of the National Academy of Sciences.

[15]  J. Joshi.  Tuberculosis chemotherapy in the 21st century: Back to the basics , 2011, Lung India : official organ of Indian Chest Society.

[16]  J. Castilla,et al.  Prion Strain Mutation Determined by Prion Protein Conformational Compatibility and Primary Structure , 2010, Science.

[17]  Charles Weissmann,et al.  Darwinian Evolution of Prions in Cell Culture , 2010, Science.

[18]  S. Prusiner,et al.  Continuous Quinacrine Treatment Results in the Formation of Drug-Resistant Prions , 2009, PLoS pathogens.

[19]  C. Soto,et al.  Prion Protein Glycosylation Is Not Required for Strain-Specific Neurotropism , 2009, Journal of Virology.

[20]  Edward Chu,et al.  A history of cancer chemotherapy. , 2008, Cancer research.

[21]  John Collinge,et al.  A General Model of Prion Strains and Their Pathogenicity , 2007, Science.

[22]  M. Fändrich,et al.  The aggregation kinetics of Alzheimer's β‐amyloid peptide is controlled by stochastic nucleation , 2005, Protein science : a publication of the Protein Society.

[23]  R. Kulkarni,et al.  Theoretical modeling of prion disease incubation. , 2001, Biophysical journal.

[24]  S. Supattapone,et al.  Pharmacological approaches to prion research. , 2002, Biochemical pharmacology.

[25]  A. McLean,et al.  Scrapie infections initiated at varying doses: an analysis of 117 titration experiments. , 2000, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[26]  V. Devita,et al.  The chemotherapy of Hodgkin's disease. Past experiences and future directions , 1978, Cancer.